Home Featured Page 255

Featured

Latest

Pα+ Psychedelic Bulletin #225: Q1 Lobbying Update; Individual vs. Group MDMA Therapy Study Launches; Australia Loosens Psychedelics Access Regulations; VA Launches “New” MDMA Trial

Three Brain Injuries, One Iboga Protocol, and What It Tells Us

The War on Drugs Was Never About Drugs. Psychedelic Healing Must Reckon With That.

A Dispatch from APA’s Annual Meeting: Psychedelics Return at an Awkward Moment for American Psychiatry

Momentum Amidst Tumult: The FDA Reshuffle, Approval Timelines, and the Compass-Usona Race

Book Review: Alexander Shulgin’s The Nature of Drugs

Nova Mentis Autism Clinical Study Approved by Canadian Institutional Review Board

MYND Life Sciences Expands Intellectual Portfolio to Target Alzheimer’s disease and...

Awakn Life Sciences to Commence Trading on the NEO Exchange under...

MindMed Appoints MGH Psychiatrist-in-Chief Dr. Maurizio Fava to Scientific Advisory Board

COMPASS Pathways becomes Founding Supporter of the British Neuroscience Association’s inaugural...

Filament Health Corp. Announces Approval for Listing on the Neo Exchange

PsyBio Therapeutics Initiates European Manufacturing of Proprietary Biosynthetic Psychedelic Compounds including...

Cybin Announces Completion of its 51st Pre-Clinical Psychedelic Molecule Study

Interview: Dr. Josh Woolley (TrPR) and Ben Lightburn (Filament Health)

EDITOR PICKS

Pα+ Psychedelic Bulletin #225: Q1 Lobbying Update; Individual vs. Group MDMA...

Three Brain Injuries, One Iboga Protocol, and What It Tells Us

The War on Drugs Was Never About Drugs. Psychedelic Healing Must...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Pα+ Psychedelic Bulletin #225: Q1 Lobbying Update; Individual vs. Group MDMA Therapy Study Launches; Australia Loosens Psychedelics Access Regulations; VA Launches “New” MDMA Trial

Three Brain Injuries, One Iboga Protocol, and What It Tells Us

The War on Drugs Was Never About Drugs. Psychedelic Healing Must Reckon With That.

A Dispatch from APA’s Annual Meeting: Psychedelics Return at an Awkward Moment for American Psychiatry

Momentum Amidst Tumult: The FDA Reshuffle, Approval Timelines, and the Compass-Usona Race

Book Review: Alexander Shulgin’s The Nature of Drugs

Nova Mentis Autism Clinical Study Approved by Canadian Institutional Review Board

MYND Life Sciences Expands Intellectual Portfolio to Target Alzheimer’s disease and...

Awakn Life Sciences to Commence Trading on the NEO Exchange under...

MindMed Appoints MGH Psychiatrist-in-Chief Dr. Maurizio Fava to Scientific Advisory Board

COMPASS Pathways becomes Founding Supporter of the British Neuroscience Association’s inaugural...

Filament Health Corp. Announces Approval for Listing on the Neo Exchange

PsyBio Therapeutics Initiates European Manufacturing of Proprietary Biosynthetic Psychedelic Compounds including...

Cybin Announces Completion of its 51st Pre-Clinical Psychedelic Molecule Study

Interview: Dr. Josh Woolley (TrPR) and Ben Lightburn (Filament Health)

EDITOR PICKS

Pα+ Psychedelic Bulletin #225: Q1 Lobbying Update; Individual vs. Group MDMA...

Three Brain Injuries, One Iboga Protocol, and What It Tells Us

The War on Drugs Was Never About Drugs. Psychedelic Healing Must...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY